Chemistry, Phylogeny, and Three-Dimensional Structure of the APOBEC Protein Family

RNA and DNA Editing: Molecular Mechanisms and Their Integration into Biological Systems

Volumn , Issue , 2007, Pages 369-419

  Macelrevey, Celeste ^a   Wedekind, Joseph E ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Nucleophilic aromatic substitution; Phylogenetic; Sequence driven analysis; Single stranded (ss) DNA

Indexed keywords

EID: 84889317673     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470262269.ch16     Document Type: Chapter

References (198)

1. Kotani, A., et al. (2007) Activation-induced cytidine deaminase (AID) promotes B cell lymphomagenesis in Emu-cmyc transgenic mice. Proc Natl Acad Sci USA 104 (5), 1616-1620.
2. Kotani, A., et al. (2005) A target selection of somatic hypermutations is regulated similarly between T and B cells upon activation-induced cytidine deaminase expression. Proc Natl Acad Sci USA 102 (12), 4506-4511.
3. Okazaki, I. M., et al. (2003) Constitutive expression of AID leads to tumorigenesis. J Exp Med 197 (9), 1173-1181.
4. Ramiro, A. R., et al. (2004) AIDis required for c-myc/IgH chromosometranslocations in vivo. Cell 118 (4), 431-438.
5. Yamanaka, S., et al. (1995) Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals. Proc Natl Acad Sci USA 92 (18), 8483-8487.
6. Yamanaka, S., et al. (1997) A novel translational repressor mRNA is edited extensively in livers containing tumors caused by the transgene expression of the apoB mRNA-editing enzyme. Genes Dev 11 (3), 321-333.
7. Skuse, G. R., et al. (1996) The neurofibromatosis type I messengerRNAundergoes base-modification RNA editing. Nucleic Acids Res 24 (3), 478-485.
8. Durandy, A. and Honjo, T. (2001) Human genetic defects in class-switch recombination (hyper-IgM syndromes). Curr Opin Immunol 13 (5), 543-548.
9. Revy, P., et al. (2000) Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell 102 (5), 565-575.
10. Zhu,Y., et al. (2003) Type two hyper-IgM syndrome caused by mutation in activation-induced cytidine deaminase. J Med Dent Sci 50 (1), 41-46.
11. Smith, A. A., et al. (1994) Mutations affecting transition-state stabilization by residues coordinating zinc at the active site of cytidine deaminase. Biochemistry 33 (21), 6468-6474.
12. Frick, L., et al. (1989) Binding of pyrimidin-2-one ribonucleoside by cytidine deaminase as the transition-state analogue 3, 4-dihydrouridine and the contribution of the 4-hydroxyl group to its binding affinity. Biochemistry 28 (24), 9423-9430.
13. Xiang, S., et al. (1995) Transition-state selectivity for a single hydroxyl group during catalysis by cytidine deaminase. Biochemistry 34 (14), 4516-4523.
14. Betts, L., et al. (1994) Cytidine deaminas. The 2. 3 Å crystal structure of an enzyme: Transition-state analog complex. J Mol Biol 235 (2), 635-656.
15. Carlow, D. C., et al. (1995) Major contribution of a carboxymethyl group to transition-state stabilization by cytidine deaminase: Mutation and rescue. Biochemistry 34 (13), 4220-4224.
16. Mian, I. S., et al. (1998) Statistical modelling and phylogenetic analysis of a deaminase domain. J Comput Biol 5 (1), 57-72.
17. Wedekind, J. E., et al. (2003) Messenger RNA editing in mammals: New members of the APOBEC family seeking roles in the family business. Trends Genet 19 (4), 207-216.
18. Xiang, S., et al. (1996) Cytidine deaminase complexed to 3-deazacytidine: A "valence buffer" in zinc enzyme catalysis. Biochemistry 35 (5), 1335-1341.
19. Berg, J. M.,Tymoczko, J. L., and Stryer, L. (2002) Biochemistry, 5th ed.,W.H. Freeman and Company, New York, p. 894.
20. Xie, K., et al. (2004) The structure of a yeast RNA-editing deaminase provide insight into the fold and function of activation-induced deaminase and APOBEC-1. Proc Natl Acad Sci USA 101 (21), 8114-8119.
21. Chothia, C., and Lesk, A. M. (1986) The relation between the divergence of sequence and structure in proteins. EMBO J 5 (4), 823-826.
22. Marti-Renom, M. A., et al. (2000) Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct 29, 291-325.
23. Berman, H. M., et al. (2000) The Protein Data Bank. Nucleic Acids Res 28 (1), 235-242.
24. Harutyunyan, E.H., Safonova, T.N., Kuranova, I.P., Popov, A.N., Teplyakov, A.V., Obmolova, G.V., Rusakov, A.A., Vainshtein, B.K., Dodson, G.G.,Wilson, J.C., and Perutz, M.F. (1995) The structure of deoxy-and oxy-leghaemoglobin from lupin. J Mol Biol 251 (1), 104-115.
25. Bashford, D., Chothia, C., and Lesk, A. M. (1987) Determinants of a protein fold: Unique features of the globin amino acid sequences. J Mol Biol 196, 199-216.
26. Flaherty, K. M., et al. (1991) Similarity of the three-dimensional structures of actin and the ATPase fragment of a 70-kDa heat shock cognate protein. Proc Natl Acad Sci USA 88, 5041-5045.
27. Holm, L. and Sander, C. (1993) Protein structure comparison by alignment of distance matrices. J Mol Biol 233 (1), 123-138.
28. Rogozin, I. B., et al. (2005) APOBEC4, a newmember of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases predicted by computational analysis. Cell Cycle 4 (9), 1281-1285.
29. Chang, B. H.andChan, L. (1998)Evolutionaryanalysis ofRNAediting enzymes. Methods 15(1),41-50.
30. Philippe, H., et al. (2005)Heterotachy and long-branch attraction in phylogenetics. BMCEvol Biol 5, 50.
31. Conticello, S. G., et al. (2005) Evolution of the AID/APOBEC family of polynucleotide (deoxy) cytidine deaminases. Mol Biol Evol 22 (2), 367-377.
32. Wang, Z. and Quiocho, F. A. (1998) Complexes of adenosine deaminase with two potent inhibitors: X-ray structures in four independent molecules at pH of maximum activity. Biochemistry 37 (23), 8314-8324.
33. Ireton, G. C., et al. (2002) The structure of Escherichia coli cytosine deaminase. J Mol Biol 315 (4), 687-697.
34. Kisker, C., et al. (1996) Aleft-hand beta-helix revealed by the crystal structure of a carbonic anhydrase from the archeon Methanosarcina thermophila. EMBO J 15, 2323-2330.
35. Scott, J., Navaratnam, N., and Carter, C. (1999) Molecular modelling of the biosynthesis of the RNAediting enzyme APOBEC-1, responsible for generating the alternative forms of apolipoprotein B. Exp Physiol 84 (4), 791-800.
36. Carter, C. W. Jr. (1998) In: Grosjean, H. and Benne, R. (eds), Nucleoside Deaminase for Cytidine and Adenosine: Comparison with Deaminases Acting on RNA. In Modification and Editing of RNA, ASM Press,Washington, D.C., pp. 591-596.
37. Jarmuz, A., et al. (2002) An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79 (3), 285-296.
38. Hache, G., Liddament, M. T., and Harris, R. S. (2005) The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. J Biol Chem 280 (12), 10920-10924.
39. Newman, E. N., et al. (2005) Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol 15 (2), 166-170.
40. Navarro, F., et al. (2005) Complementary function of the two catalytic domains of APOBEC3G. Virology 333 (2), 374-386.
41. Johansson, E., et al. (2002) Crystal structure of the tetrameric cytidine deaminase from Bacillus subtilis at 2.0 Å resolution. Biochemistry 41 (8), 2563-2570.
42. Chung, S. J., Fromme, J. C., andVerdine, G. L. (2005) Structure of human cytidine deaminase bound to a potent inhibitor. J Med Chem 48 (3), 658-660.
43. Teh, A. H., et al. (2006) The 1.48 Å resolution crystal structure of the homotetrameric cytidine deaminase from mouse. Biochemistry 45 (25), 7825-7833.
44. Kurtz, J. E., et al. (1999) New insights into the pyrimidine salvage pathway of Saccharomyces cerevisiae: Requirement of six genes for cytidine metabolism. Curr Genet 36 (3), 130-136.
45. Dance, G. S., et al. (2001) Identification of the yeast cytidine deaminase CDD1 as an orphan C!U RNA editase. Nucleic Acids Res 29 (8), 1772-1780.
46. Oka, K., et al. (1997) Tissue-specific inhibition of apolipoprotein B mRNA editing in the liver by adenovirus-mediated transfer of a dominant negative mutant APOBEC-1leads to increased lowdensity lipoprotein in mice. J Biol Chem 272 (3), 1456-1460.
47. Harris, R. S., Petersen-Mahrt, S. K., and Neuberger, M. S. (2002) RNAediting enzymeAPOBEC1and some of its homologs can act as DNA mutators. Mol Cell 10 (5), 1247-1253.
48. Petersen-Mahrt, S. K., Harris, R. S., and Neuberger,M. S. (2002) AIDmutates E. coli suggesting aDNA deamination mechanism for antibody diversification. Nature 418 (6893), 99-103.
49. Smith, H. C., Wedekind, J. E., Xie, K., and Sowden, M. P. (2005) Fine-tuning of RNA functions by modification and editing in mammalian C to U editing. In: Grosjean H. (ed.), Topics in Current Genetics, Springer-Verlag, Berlin, pp. 1610-2096.
50. Zaim, J. and Kierzek, A. M.(2003)Domainorganization of activation-induced cytidine deaminase. Nat Immunol 4 (12), author reply on p. 1153-1154.
51. Chen, S. C., et al. (2006) Crystal structure of a bifunctional deaminase and reductase from Bacillus subtilis involved in riboflavin biosynthesis. J Biol Chem 281 (11), 7605-7613.
52. Prochnow, C., et al. (2007) The APOBEC-2 crystal structure and functional implications for the deaminase AID. Nature 445 (7126), 447-451.
53. Murzin, A. G., et al. (1995) SCOP:Astructural classification of proteins database for the investigation of sequences and structures. J Mol Biol 247 (4), 536-540.
54. Macbeth, M. R., et al. (2005) Inositol hexakisphosphate is bound in the ADAR2 core and required for RNA editing. Science 309 (5740), 1534-1539.
55. Kim, J., et al. (2006) Structural and kinetic characterization of Escherichia coli TadA, the wobblespecific tRNA deaminase. Biochemistry 45 (20), 6407-6416.
56. Huthoff, H., and Malim, M. H. (2007) Identification of amino acid residues inAPOBEC3Grequired for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation. J Virol 81 (8), 3807-3815.
57. Sheehy, A. M., Gaddis, N. C., and Malim, M. H. (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 9 (11), 1404-1407.
58. Liu, B., et al. (2005) Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase. J Virol 79 (15), p. 9579-9587.
59. Almog, R., et al. (2004) Three-dimensional structure of the R115E mutant of T4-bacteriophage 20-deoxycytidylate deaminase. Biochemistry 43 (43), 13715-13723.
60. Eliopoulos, N., Cournoyer, D., and Momparler, R. L. (1998) Drug resistance to 5-aza-20-deoxycytidine, 20,20-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells. Cancer Chemother Pharmacol 42 (5), 373-378.
61. Greco, O. and Dachs, G. U. (2001) Gene directed enzyme/prodrug therapy of cancer: Historical appraisal and future prospectives. J Cell Physiol 187 (1), 22-36.
62. Liou, J. Y., et al. (2003) Assessment of the effect of phosphorylated metabolites of anti-human immunodeficiency virus and anti-hepatitis B virus pyrimidine analogs on the behavior of human deoxycytidylate deaminase. Mol Pharmacol 63 (1), 105-110.
63. Vauthey, J. N., et al. (1996) Arterial therapy of hepatic colorectal metastases. Br J Surg 83 (4), 447-455.
64. Ko, T. P., et al. (2003) Crystal structure of yeast cytosine deaminase. Insights into enzyme mechanism and evolution. J Biol Chem 278 (21), 19111-19117.
65. Liaw, S. H., et al. (2004) Crystal structure of Bacillus subtilis guanine deaminase: The first domainswapped structure in the cytidine deaminase superfamily. J Biol Chem 279 (34), 35479-35485.
66. Kuratani, M., et al. (2005) Crystal structure of tRNA adenosine deaminase (TadA) from Aquifex aeolicus. J Biol Chem 280 (16), 16002-16008.
67. Bennett, M. J., Choe, S., and Eisenberg, D. (1994) Refined structure of dimeric diphtheria toxin at 2. 0 A resolution. Protein Sci 3 (9), 1444-1463.
68. Liu,Y. and Eisenberg, D. (2002) 3Ddomain swapping: Asdomains continue to swap. Protein Sci 11 (6), 1285-1299.
69. Moore, J. T., et al. (1994) Identification of a site necessary for allosteric regulation in T4-phage deoxycytidylate deaminase. Biochemistry 33 (8), 2104-2112.
70. Keefe, R. G., et al. (2000) A T4-phage deoxycytidylate deaminase mutant that no longer requires deoxycytidine 50-triphosphate for activation. J Biol Chem 275 (17), 12598-12602.
71. Mora,P., Rubio,V., and Cervera, J. (2002)Mechanismof oligomerization of Escherichia coli carbamoyl phosphate synthetase and modulation by the allosteric effectors. A site-directed mutagenesis study. FEBS Lett 511 (1-3), 6-10.
72. Kashlan, O. B., et al. (2002) A comprehensive model for the allosteric regulation of mammalian ribonucleotide reductase. Functional consequences of ATP-and dATP-induced oligomerization of the large subunit. Biochemistry 41 (2), 462-474.
73. Bransteitter, R., et al. (2003) Activation-induced cytidine deaminase deaminates deoxycytidine on single-stranded DNA but requires the action of RNase. Proc Natl Acad Sci USA 100 (7), 4102-4107.
74. Soros,V. B.,Yonemoto,W., and Greene,W. C., (2007)Newly synthesizedAPOBEC3Gis incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS Pathog 3 (2), e15.
75. Lo Conte, L., Chothia, C., and Janin, J. (1999) The atomic structure of protein-protein recognition sites. J Mol Biol 285 (5), 2177-2198.
76. Cheong, C. G., et al. (2004) Crystal structures of human bifunctional enzyme aminoimidazole-4-carboxamide ribonucleotide transformylase/IMP cyclohydrolase in complex with potent sulfonylcontaining antifolates. J Biol Chem 279 (17), 18034-18045.
77. Keegan, L. P., et al. (2004) Adenosine deaminases acting on RNA (ADARs): RNA-editing enzymes. Genome Biol 5 (2), 209.
78. Adams, M. J., et al. (1970) Structure of lactate dehydrogenase at 2-8Åresolution. Nature 227 (5263), 1098-1103.
79. Adams, M. J., et al. (1970) The structure of the nicotinamide-adenine dinucleotide coenzyme when bound to lactate dehydrogenase. J Mol Biol 51 (1), 31-38.
80. Stockwell, G. R. and Thornton, J. M. (2006) Conformational diversity of ligands bound to proteins. J Mol Biol 356 (4), 928-944.
81. Richter, G., et al. (1997) Biosynthesis of riboflavin: Characterization of the bifunctional deaminasereductase of Escherichia coli and Bacillus subtilis. J Bacteriol 179 (6), 2022-2028.
82. Cho, D. S., et al. (2003) Requirement of dimerization forRNAediting activity of adenosine deaminases acting on RNA. J Biol Chem 278 (19), 17093-17102.
83. Gallo, A., et al. (2003) An ADAR that edits transcripts encoding ion channel subunits functions as a dimer. EMBO J 22 (13), 3421-3430.
84. Chilibeck, K. A., et al. (2006) FRET analysis of in vivo dimerization by RNA-editing enzymes. J Biol Chem 281 (24), 16530-16535.
85. Valente, L. and Nishikura, K. (2007) RNA-Binding independent dimerization of ADAR and dominant negative effects of nonfunctional subunits on dimer functions. J Biol Chem 282 (22), 16054-16061.
86. Babbitt, P. C., et al. (1996) The enolase superfamily: A general strategy for enzyme-catalyzed abstraction of the alpha-protons of carboxylic acids. Biochemistry 35 (51), 16489-16501.
87. Farber, G. K. and Petsko, G. A. (1990) The evolution of alpha/beta barrel enzymes. Trends Biochem Sci 15 (6), 228-234.
88. Smith, H. C. (2007) Measuring editing activity and identifyingCtoUmRNAediting factors in cells and biochemical isolates. In: Gott J. M. (ed.), In: Methods in Enzymology, RNA Editing & Modification, Academic Press, New York, pp. 390-419.
89. Dance, G. S., et al. (2000) APOBEC-1dependent cytidine to uridine editing of apolipoproteinBRNAin yeast. Nucleic Acids Res 28 (2), 424-429.
90. Yamanaka, S., et al. (1996) Hyperediting of multiple cytidines of apolipoprotein B mRNA by APOBEC-1 requires auxiliary protein(s) but not a mooring sequence motif. J Biol Chem 271 (19), 11506-11510.
91. Siddiqui, J. F., et al. (1999) Disproportionate relationship between APOBEC-1 expression and apolipoprotein B mRNA editing activity. Exp Cell Res 252 (1), 154-164.
92. Sowden, M., Hamm, J. K., and Smith, H. C. (1996) Overexpression of APOBEC-1 results in mooring sequence-dependent promiscuous RNA editing. J Biol Chem 271 (6), 3011-3017.
93. Sowden, M. P., Eagleton, M. J., and Smith, H. C. (1998) Apolipoprotein B RNA sequence 30 of the mooring sequence and cellular sources of auxiliary factors determine the location and extent of promiscuous editing. Nucleic Acids Res 26 (7), 1644-1652.
94. Losey, H. C., Ruthenburg, A. J., and Verdine, G. L. (2006) Crystal structure of Staphylococcus aureus tRNA adenosine deaminase TadA in complex with RNA. Nat Struct Mol Biol 13 (2), 153-159.
95. Stephens, O. M., Yi-Brunozzi, H. Y., and Beal, P. A. (2000) Analysis of the RNA-editing reaction of ADAR2with structural and fluorescent analogues of the GluR-BR/Gediting site. Biochemistry 39 (40), 12243-12251.
96. Gillespie, J. H. (1984) The molecular clock may be an episodic clock. Proc Natl Acad Sci USA 81 (24), 8009-8013.
97. Gillespie, J. H. (1986) Natural selection and the molecular clock. Mol Biol Evol 3 (2), 138-155.
98. Hurst, L. D. (2002) The Ka/Ks ratio: Diagnosing the form of sequence evolution. Trends Genet 18 (9), 486.
99. Van Valen, L. (1973) A new evolutionary law. Evol Theory 1, 1-30.
100. Petersen-Mahrt, S. K. and Neuberger, M. S. (2003) In vitro deamination of cytosine to uracil in singlestrandedDNAby apolipoproteinBediting complex catalytic subunit 1 (APOBEC1). J Biol Chem 278 (22), 19583-19586.
101. Beale, R. C., et al. (2004) Comparison of the differential context-dependence ofDNAdeamination by APOBEC enzymes: Correlation with mutation spectra in vivo. J Mol Biol 337 (3), 585-596.
102. Yu, Q., et al. (2004) APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J Biol Chem 279 (51), 53379-53386.
103. Muramatsu, M., et al. (1999) Specific expression of activation-induced cytidine deaminase (AID), a novel member of theRNA-editing deaminase family in germinal centerBcells. J Biol Chem 274 (26), 18470-18476.
104. Muto, T., et al. (2000) Isolation, tissue distribution, and chromosomal localization of the human activation-induced cytidine deaminase (AID) gene. Genomics 68 (1), 85-88.
105. Muramatsu, M., et al. (2000) Class switch recombination and hypermutation require activationinduced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102 (5), 553-563.
106. Flajnik,M. F. (2002) Comparative analyses ofimmunoglobulin genes: Surprises and portents. Nat Rev Immunol 2 (9), 688-698.
107. Saunders, H. L. and Magor, B. G. (2004) Cloning expression of the AID gene in the channel catfish. Dev Comp Immunol 28 (7-8), 657-663.
108. Zhao,Y., et al. (2005) Identification of the activation-induced cytidine deaminase gene from zebrafish: An evolutionary analysis. Dev Comp Immunol 29 (1), 61-71.
109. Sawyer, S. L., Emerman, M., and Malik, H. S. (2004) Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol 2 (9), E275.
110. Rogozin, I. B., et al. (2007) Evolution and diversification of lamprey antigen receptors: evidence for involvement of an AID-APOBEC family cytosine deaminase. Nat Immunol. 8 (6), 647-656.
111. Hedges, S. B. (2001) In: Ahlberg, P. E. (ed.), Major Events in Early Vertebrate Evolution, Taylor & Francis, London, pp. 119-134.
112. Reeves, R. and Nissen, M. S. (1990) The A. T-DNA-binding domain of mammalian high mobility group I chromosomal proteins.Anovel peptide motif for recognizingDNAstructure. J Biol Chem 265 (15), 8573-8582.
113. Aravind, L. and Landsman, D. (1998) AT-hook motifs identified in a wide variety of DNA-binding proteins. Nucleic Acids Res 26 (19), 4413-4421.
114. Azumi, K., et al. (2003) Genomic analysis of immunity in a Urochordate and the emergence of the vertebrate immune system: "Waiting for Godot." Immunogenetics 55 (8), 570-581.
115. Wang, J., et al. (2006) Identification of a specific domain required for dimerization of activationinduced cytidine deaminase. J Biol Chem 281 (28), 19115-19123.
116. Liao, W., et al. (1999) APOBEC-2, a cardiac-and skeletal muscle-specific member of the cytidine deaminase supergene family. Biochem Biophys Res Commun 260 (2), 398-404.
117. Anant, S., et al. (2001) ARCD-1, an apobec-1-related cytidine deaminase, exerts a dominant negative effect on C to U RNA editing. Am J Physiol Cell Physiol 281 (6), C1904-C1916.
118. Taylor, J. S., et al. (2003) Genome duplication, a trait shared by 22000 species of ray-finned fish. Genome Res 13 (3), 382-390.
119. Christoffels, A., et al. (2004) Fugu genome analysis provides evidence for a wholegenome duplication early during the evolution of ray-finned fishes. Mol Biol Evol 21 (6), 1146-1151.
120. Matsumoto, T., et al. (2006) Expression of APOBEC2 is transcriptionally regulated by NF-kappaB in human hepatocytes. FEBS Lett 580 (3), 731-735.
121. Mikl, M. C., et al. (2005) Mice deficient in APOBEC2 and APOBEC3. Mol Cell Biol 25 (16), 7270-7277.
122. Teng, B., Burant, C. F., and Davidson, N. O. (1993) Molecular cloning of an apolipoprotein B messenger RNA editing protein. Science 260 (5115), 1816-1819.
123. Navaratnam, N., et al. (1993) The p27 catalytic subunit of the apolipoproteinBmRNAediting enzyme is a cytidine deaminase. J Biol Chem 268 (28), 20709-20712.
124. Chen, S. H., et al. (1987) Apolipoprotein B-48 is the product of a messenger RNA with an organ-specific in-frame stop codon. Science 238 (4825), 363-366.
125. Powell, L. M., et al. (1987) Anovel form of tissue-specificRNAprocessing produces apolipoprotein-B48 in intestine. Cell 50 (6), 831-840.
126. Sowden, M. P., et al. (2002) The editosome for cytidine to uridine mRNA editing has a native complexity of 27S:identification of intracellular domains containing active and inactive editing factors. J Cell Sci 115 (Pt 5), 1027-1039.
127. Mehta, A. and Driscoll, D. M.(1998)Asequence-specificRNA-binding proteincomplements apobec-1 To edit apolipoprotein B mRNA. Mol Cell Biol 18 (8), 4426-4432.
128. Hersberger, M., Patarroyo-White, S., Arnold, K. S. and., and Innerarity, T. L. (1999) Phylogenentic Analysis of the Apolipoprotein B mRNA-editing Region. J Biol Chem 274 (49), 34590-34597.
129. Maris, C., et al. (2005) NMRstructure of the apoBmRNAstem-loop and its interaction with theCtoU editing APOBEC1 complementary factor. RNA 11 (2), 173-186.
130. Greeve, J., et al. (1993) Apolipoprotein B mRNA editing in 12 different mammalian species: Hepatic expression is reflected in low concentrations of apoB-containing plasma lipoproteins. J Lipid Res 34 (8), 1367-1383.
131. Nakamuta, M., et al. (1995) Alternative mRNA splicing and differential promoter utilization determine tissue-specific expression of the apolipoprotein B mRNA-editing protein (Apobec1) gene in mice. Structure and evolution of Apobec1 and related nucleoside/nucleotide deaminases. J Biol Chem 270 (22), 13042-13056.
132. Espinosa, R. 3rd., et al. (1994) Assignment of the gene encoding the human apolipoprotein BmRNA editing enzyme (APOBEC1) to chromosome 12p13.1. Genomics 24 (2), 414-415.
133. Lau, P. P., et al. (1994) Dimeric structure of a human apolipoprotein B mRNA editing protein and cloning and chromosomal localization of its gene. Proc Natl Acad Sci USA 91 (18), 8522-8526.
134. Fujino, T., et al. (1999) C!U editing of apolipoprotein B mRNA in marsupials: identification and characterisation of APOBEC-1 from the American opossum Monodelphus domestica. Nucleic Acids Res 27 (13), 2662-2671.
135. Kumar, S. and Hedges, S. B. (1998) A molecular timescale for vertebrate evolution. Nature 392 (6679), 917-920.
136. Yang,Y., Sowden,M. P., and Smith, H. C. (2001) Intracellular trafficking determinants inAPOBEC-1, the catalytic subunit for cytidine to uridine editing of apolipoprotein B mRNA. Exp Cell Res 267 (2), 153-164.
137. Teng, B. B., et al. (1999) Mutational analysis of apolipoprotein B mRNA editing enzyme (APOBEC1). structure-function relationships of RNA editing and dimerization. J Lipid Res 40 (4), 623-635.
138. Navaratnam, N., et al. (1998) Escherichia coli cytidine deaminase provides a molecular model for ApoB RNA editing and a mechanism for RNA substrate recognition. J Mol Biol 275 (4), 695-714.
139. Navaratnam, N., et al. (1995) Evolutionary origins of apoB mRNA editing: Catalysis by a cytidine deaminase that has acquired a novel RNA-binding motif at its active site. Cell 81 (2), 187-195.
140. Turelli, P., et al. (2004) Inhibition of hepatitisBvirus replication byAPOBEC3G. Science 303 (5665), 1829.
141. Suspene, R., et al. (2005) Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc Natl Acad Sci USA 102 (23), 8321-8326.
142. Mangeat, B., et al. (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424 (6944), 99-103.
143. Hulme, A. E., et al. (2007) Selective inhibition of Alu retrotransposition by APOBEC3G. Gene 390 (1-2), 199-205.
144. Nguyen, D. H., Gummuluru, S., and Hu, J. (2007) Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G. J Virol 81 (9), 4465-4472.
145. Bogerd, H. P., et al. (2007) The intrinsic antiretroviral factorAPOBEC3Bcontains two enzymatically active cytidine deaminase domains. Virology 364 (2), 486-493.
146. Bogerd, H. P., et al. (2006) Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. Proc Natl Acad Sci USA 103 (23), 8780-8785.
147. Dang,Y., et al. (2006) Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J Virol 80 (21), 10522-10533.
148. Liddament, M. T., et al. (2004) APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr Biol 14 (15), 1385-1391.
149. OhAinle, M., et al. (2006) Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H. J Virol 80 (8), 3853-3862.
150. Chen, H., et al. (2006) APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr Biol 16 (5), 480-485.
151. Hurles, M. (2004) Gene duplication: The genomic trade in spare parts. PLoS Biol 2 (7), E206.
152. Murphy,W. J., Pevzner, P. A., and O'Brien, S. J. (2004) Mammalian phylogenomics comes of age. Trends Genet 20 (12), 631-639.
153. Glazko, G. V., Rogozin, I. B., and Glazkov, M. V. (2001) Comparative study and prediction of DNA fragments associated with various elements of the nuclear matrix. Biochim Biophys Acta 1517 (3), 351-364.
154. Jaillon, O., et al. (2004) Genome duplication in the teleost fish Tetraodon nigroviridis reveals the early vertebrate proto-karyotype. Nature 431 (7011), 946-957.
155. OhAinle, M., Emerman, M., and Malik, H. (2007) Evolution of antiretroviral Activity of APOBEC genes in primates. In: Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA.
156. Sibley, C. G. and Ahlquist, J. E. (1984) The phylogeny of the hominoid primates, as indicated by DNA-DNA hybridization. J Mol Evol 20 (1), 2-15.
157. Mariani, R., et al. (2003) Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114 (1), 21-31.
158. Jonsson, S. R., et al. (2006) Evolutionarily conserved and non-conserved retrovirus restriction activities of artiodactyl APOBEC3F proteins. Nucleic Acids Res 34 (19), 5683-5694.
159. Lochelt, M., et al. (2005) The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein. Proc Natl Acad Sci USA 102 (22), 7982-7987.
160. Hakata, Y. and Landau, N. R. (2006) Reversed functional organization of mouse and human APOBEC3 cytidine deaminase domains. J Biol Chem 281 (48), 36624-36631.
161. Bonvin, M., et al. (2006) Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology 43 (6), 1364-1374.
162. Kinomoto, M., et al. (2007) All APOBEC3 family proteins differentially inhibit LINE-1 retrotransposition. Nucleic Acids Res 35 (9), 2955-2964.
163. Noguchi, C., et al. Dual effect of APOBEC3G on hepatitis B virus. J Gen Virol (2007) 88 (Pt 2), 432-432.
164. Bailey, J. A., et al. (2002) Human-specific duplication and mosaic transcripts: The recent paralogous structure of chromosome 22. Am J Hum Genet 70 (1), 83-100.
165. Kidd, J. M., et al. (2007) Population Stratification of a Common APOBEC Gene Deletion Polymorphism. PLoS Genet 3 (4), e63.
166. Bailey, J. A., Liu, G., and Eichler, E. E. (2003) AnAlu transpositionmodel for the origin and expansion of human segmental duplications. Am J Hum Genet 73 (4), 823-834.
167. Eichler, E. E. (2001) Recent duplication, domain accretion and the dynamic mutation of the human genome. Trends Genet 17 (11), 661-669.
168. Stankiewicz,P. and Lupski, J. R. (2002) Genomearchitecture, rearrangements and genomic disorders. Trends Genet 18 (2), 74-82.
169. Zhang, J. andWebb, D. M. (2004) Rapid evolution of primate antiviral enzyme APOBEC3G. Hum Mol Genet 13 (16), 1785-1791.
170. Lander, E. S., et al. (2001) Initial sequencing and analysis of the human genome. Nature 409 (6822), 860-921.
171. Bailey, J. A. and Eichler, E. E. (2006) Primate segmental duplications: Crucibles of evolution, diversity and disease. Nat Rev Genet 7 (7), 552-564.
172. Grover, D., et al. (2004) Alu repeat analysis in the completehumangenome:Trends and variations with respect to genomic composition. Bioinformatics 20 (6), 813-817.
173. Scherer, S. E., et al. (2006) The finishedDNAsequence ofhumanchromosome12. Nature 440 (7082), 346-351.
174. Wienberg, J. (2005) Fluorescence in situ hybridization to chromosomes as a tool to understand human and primate genome evolution. Cytogenet Genome Res 108 (1-3), 139-160.
175. Wedekind, J. E., et al. (2006) Nanostructures ofAPOBEC3Gsupport a hierarchical assembly modelof high molecular mass ribonucleoprotein particles from dimeric subunits. J Biol Chem 281 (50), 38122-38126.
176. Chiu, Y. L., et al. (2005) Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 435 (7038), 108-114.
177. Chiu, Y. L., et al. (2006) High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc Natl Acad Sci USA 103 (42), 15588-15593.
178. Kreisberg, J. F.,Yonemoto,W., and Greene,W. C. (2006) Endogenous factors enhance HIVinfection of tissue naiveCD4Tcells by stimulating high molecular massAPOBEC3Gcomplex formation. JExp Med 203 (4), 865-870.
179. Cullen, B. R. (2006) Role mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J Virol 80 (3), 1067-1076.
180. Esnault, C., et al. (2005) APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature 433 (7024), 430-433.
181. Kozak, S. L., et al. (2006) The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules. J Biol Chem 281 (39), 29105-29115.
182. Chelico, L., et al. (2006) APOBEC3G DNA deaminase acts processively 30!50 on single-stranded DNA. Nat Struct Mol Biol 13 (5), 392-399.
183. Opi, S., et al. (2006) Monomeric APOBEC3G is catalytically active and has antiviral activity. J Virol 80 (10), 4673-4682.
184. Bishop, K. N., Holmes, R. K., and Malim, M. H. (2006) Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J Virol 80 (17), 8450-8458.
185. Guo,F., et al. (2006) Inhibition of formula-primedreverse transcription by humanAPOBEC3Gduring human immunodeficiency virus type 1 replication. J Virol 80 (23), 11710-11722.
186. Sheehy, A. M., et al. (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418 (6898), 646-650.
187. Yang, Z. (2005) The power of phylogenetic comparison in revealing protein function. Proc Natl Acad Sci USA 102 (9), 3179-3180.
188. Ortiz, M., et al. (2006) Patterns of evolution of host proteins involved in retroviral pathogenesis. Retrovirology 3, 11.
189. Bogerd, H. P., et al. (2004) Asingle amino acid difference in the hostAPOBEC3Gprotein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc Natl Acad Sci USA 101 (11), 3770-3774.
190. Mangeat, B., et al. (2004) A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J Biol Chem 279 (15), 14481-14483.
191. Marin, M., et al. (2003) HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 9 (11), 1398-1403.
192. Schrofelbauer, B., Chen, D., and Landau, N. R. (2004) Asingle amino acid ofAPOBEC3Gcontrols its species-specific interaction with virion infectivity factor (Vif). Proc Natl Acad Sci USA 101 (11), 3927-3932.
193. Xu, H., et al. (2004) A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc Natl Acad Sci USA 101 (15), 5652-5657.
194. Schrofelbauer, B., et al. (2006) Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. J Virol 80 (12), 5984-5991.
195. Katzourakis, A., et al. (2007) Fromthe cover: discovery and analysis of the first endogenous lentivirus. Proc Natl Acad Sci USA 104 (15), 6261-6265.
196. Wiegand, H. L., et al. (2004) Asecond human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J 23 (12), 2451-2558.
197. Schumacher, A. J., Nissley, D. V., and Harris, R. S. (2005) APOBEC3Ghypermutates genomicDNA and inhibits Ty1 retrotransposition in yeast. Proc Natl Acad Sci USA 102 (28), 9854-9859.
198. Guex, N. and Peitsch, M. C. (1997) SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling. Electrophoresis 18 (15), 2714-2723.